With an estimated 74.5 million people afflicted with hypertension in the U.S., and some of these unable to control their condition via lifestyle modifications or medication, the market for a vaccine that would prevent the risks of mortality and severe symptoms associated with this illness appears extremely large.
Two vaccines have moved into Phase II clinical testing. Although many product candidates at this stage fail to gain approval, other developers will build upon the pioneering work in order to gain access to this significant opportunity.
With 250 million cases each year combined with severe symptoms and relatively high mortality, malaria has long been the subject of healthcare initiatives ranging from drug and vaccine development to the deployment of mosquito nets to prevent infection.
As of late 2009, the most advanced vaccine candidate was GlaxoSmithKline’s Mosquirix, a Phase III product that is likely to be approved in 2012. When this occurs, sales are expected to rise strongly to reach nearly $2 billion in 2020.
MRSA infection is a growing problem. Although it currently affects a total of just 4 million people globally, incidence is rising and within a decade MRSA could be considerably more prevalent.
Earlier this year, Nabi Biopharmaceuticals sold its PentaStaph vaccine candidate, which is in Phase I trials, to GlaxoSmithKline Biologicals. Assuming this product is introduced in 2016, global sales are expected to rise to $650 million as awareness of the dangers of MRSA rises.